Food craving and consumption evolution in patients starting treatment with clozapine

Garriga, Marina; Mallorquí, Andrea; Serrano, Lourdes; Ríos, José; Salamero, Manel; Parellada, Eduard; Gómez-Ramiro, Marta; Oliveira, Cristina; Amoretti, Sílvia; Vieta, Eduard; Bernardo, Miquel; García-Rizo, Clemente

doi:10.1007/s00213-019-05291-3

Cited by 9 publications

(24 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The case-control studies recruited healthy controls without history of mental illness. There were four cohort studies [40,41,54,60], with followup periods ranging from 10 weeks to 6 months. Three studies [28,46,57] reported results from clinical trials.…”

Section: Resultsmentioning

confidence: 99%

“…Twenty-seven studies [17,26,[28][29][30][35][36][37][38][39][40][41][42]44,55,57,60] were performed in patients with a diagnosis of schizophrenia or SSD, and four studies included patients with multiple diagnoses [43,56,58,59]. The majority of the studies used DSM-IV criteria (n = 20), followed by ICD-10 (n = 3); one multisite study [60] used both DSM-IV and ICD-10 criteria.…”

Section: Sample Characteristicsmentioning

confidence: 99%

“…Five studies did not describe the diagnostic criteria used [28,38,42,43,56]. In around half of the studies (n = 13), participants were recruited from community or outpatient settings [29,36,38,42,44,45,48,[50][51][52][53]56,60], while eight studies employed hospital or inpatient settings [17,26,30,40,43,49,58,59], and three studies recruited from multiple locations [35,41,55]. Seven studies [28,37,39,46,47,54,57] either were unclear or did not specify where participants were recruited from.…”

Section: Sample Characteristicsmentioning

confidence: 99%

“…The majority of the studies (n = 15) included more men [28][29][30]35,[37][38][39]41,42,47,48,50,53,55,59]. All studies were of adults, apart from the study of Bachman et al [37], which was of a child and adolescent population with a mean (SD) age of 19.2 (2.3) years for males and 19.7 (2.6) years for females.…”

Section: Sample Characteristicsmentioning

confidence: 99%

“…All studies were of adults, apart from the study of Bachman et al [37], which was of a child and adolescent population with a mean (SD) age of 19.2 (2.3) years for males and 19.7 (2.6) years for females. The majority of the other studies included participants who were in their 30s [30,35,[39][40][41][44][45][46][47]49,[53][54][55]60] and 40s [26,36,38,48,51,52,56,57]. Case et al [28] described data from four trials and participant age varied across sites.…”

Section: Sample Characteristicsmentioning

confidence: 99%

See 4 more Smart Citations

Disordered Eating among People with Schizophrenia Spectrum Disorders: A Systematic Review

Sankaranarayanan

Johnson²,

Mammen³

et al. 2021

Nutrients

View full text Add to dashboard Cite

Disordered eating, or abnormal eating behaviours that do not meet the criteria for an independent eating disorder, have been reported among people with schizophrenia. We aimed to systemati-cally review literature on disordered eating among people with schizophrenia spectrum disorder (SSD). Seven databases were systematically searched for studies that described the prevalence and correlates of disordered eating among patients with SSD from January 1984 to 15 February 2021. Qualitative analysis was performed using the National Institutes of Health scales. Of 5504 records identified, 31 studies involving 471,159 subjects were included in the systematic review. The ma-jority of studies (17) rated fair on qualitative analysis and included more men, and participants in their 30s and 40s, on antipsychotics. The commonest limitations include lack of sample size or power calculations, poor sample description, not using valid tools, or not adjusting for con-founders. The reported rates were 4.4% to 45% for binge eating, 16.1% to 64%, for food craving, 27% to 60.6% for food addiction, and 4% to 30% for night eating. Positive associations were re-ported for binge eating with antipsychotic use and female gender, between food craving and weight gain, between food addiction and increased dietary intake, and between disordered eating and female gender, mood and psychotic symptoms. Reported rates for disordered eating among people with SSD are higher than those in the general population. We will discuss the clinical, treatment and research implications of our findings.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Sample Characteristicsmentioning

confidence: 99%

Section: Sample Characteristicsmentioning

confidence: 99%

Section: Sample Characteristicsmentioning

confidence: 99%

Section: Sample Characteristicsmentioning

confidence: 99%

See 3 more Smart Citations

Disordered Eating among People with Schizophrenia Spectrum Disorders: A Systematic Review

Sankaranarayanan

Johnson²,

Mammen³

et al. 2021

Nutrients

View full text Add to dashboard Cite

show abstract

Naringin treatment improved main clozapine‐induced adverse effects in rats; emphasis on weight gain, metabolic abnormalities, and agranulocytosis

George

Menze

Esmat

et al. 2021

Drug Development Research

View full text Add to dashboard Cite

Schizophrenia is one of the major neuropsychiatric disorders affecting people worldwide. Unfortunately, currently available antipsychotic medications possess several side effects. Among them, clozapine is one of the atypical antipsychotics prescribed in schizophrenia wing to its blocking effect on dopamine (D2) and serotonin (5‐HT1c) receptors. However, it has been recently reserved for resistant schizophrenia due to its several side effects. The current research aimed at investigating potential naringin add‐on benefit to cease the main side effects of clozapine in ketamine‐induced psychosis in rats. In this study, schizophrenia was induced in rats via ketamine administration that could promote neuropathological patterns of schizophrenia. Afterwards, clozapine and naringin were administered to rats in order to improve such effects induced by ketamine. Clozapine administration promoted weight gain, hyperglycemia, dyslipidemia, and agranulocytosis. However, naringin was able to reduce such adverse effects when added to clozapine treatment. Naringin increased total leukocyte count preventing agranulocytosis either when administered alone or in combination with clozapine. In addition, via its metabolic activities, naringin treatment lowered serum total cholesterol and triglycerides levels. Moreover, naringin prevented weight gain when administered. Finally, naringin reduced serum glucose level preventing hyperglycemia associated with clozapine treatment. Collectively, these findings may suggest that naringin possesses a potential add‐on benefit to clozapine in treatment of schizophrenia.

show abstract

Lifestyle behaviors, metabolic disturbances, and weight gain in psychiatric inpatients treated with weight gain-associated medication

Simon

Barton

Zagler

et al. 2022

Eur Arch Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Many psychiatric patients suffer from overweight/obesity and subsequent metabolic disturbances, where psychotropic medication is one of the main contributors. However, the magnitude of weight gain ranges individually, which leads to questioning the role of other contributors like lifestyle factors. The present study investigated several lifestyle factors among psychiatric inpatients, their relation to biological factors, and their predictive capability for weight gain during treatment. Using a naturalistic observational study design, psychiatric inpatients of all diagnoses were followed for 4 weeks from the start of treatment with weight gain-associated medication. N = 163 participants entered the study. Lifestyle factors were assessed by patient self-report questionnaires. Body weight change over time was calculated relative to baseline body weight. Our study provides three main findings: (1) Obesity and/or metabolic syndrome (metSy) were associated with emotional eating (disinhibition), craving for fast food and sweets, and weight cycling. (2) Patients without metSy and normal BMI experienced increased sweets craving (also for women), a more positive attitude towards drugs, and an improvement of affect (also for men). (3) Sex, presence of metSy and/or drug dosage interacted with disinhibition change, sweets craving change (trend), and fast food craving change to predict weight change over time. Furthermore, drug attitude change interacted with BMI, drug dosage, and presence of metSy to predict weight change. Lifestyle factors, especially eating behaviors, are related to metabolic disturbances and predict weight gain in interaction with clinical parameters.

show abstract

Food craving and consumption evolution in patients starting treatment with clozapine

Cited by 9 publications

References 37 publications

Disordered Eating among People with Schizophrenia Spectrum Disorders: A Systematic Review

Disordered Eating among People with Schizophrenia Spectrum Disorders: A Systematic Review

Naringin treatment improved main clozapine‐induced adverse effects in rats; emphasis on weight gain, metabolic abnormalities, and agranulocytosis

Lifestyle behaviors, metabolic disturbances, and weight gain in psychiatric inpatients treated with weight gain-associated medication

Contact Info

Product

Resources

About